000867774 001__ 867774
000867774 005__ 20220930130224.0
000867774 0247_ $$2doi$$a10.3390/molecules24244551
000867774 0247_ $$2Handle$$a2128/23880
000867774 0247_ $$2altmetric$$aaltmetric:72796756
000867774 0247_ $$2pmid$$apmid:31842406
000867774 0247_ $$2WOS$$aWOS:000507299600129
000867774 037__ $$aFZJ-2019-06384
000867774 082__ $$a540
000867774 1001_ $$0P:(DE-Juel1)180244$$aOlubiyi, Olujide$$b0$$eCorresponding author$$ufzj
000867774 245__ $$aRational Drug Design of Peptide-Based Therapies for Sickle Cell Disease
000867774 260__ $$aBasel$$bMDPI$$c2019
000867774 3367_ $$2DRIVER$$aarticle
000867774 3367_ $$2DataCite$$aOutput Types/Journal article
000867774 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1579157348_6402
000867774 3367_ $$2BibTeX$$aARTICLE
000867774 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000867774 3367_ $$00$$2EndNote$$aJournal Article
000867774 520__ $$aSickle cell disease (SCD) is a group of inherited disorders affecting red blood cells, which is caused by a single mutation that results in substitution of the amino acid valine for glutamic acid in the sixth position of the β-globin chain of hemoglobin. These mutant hemoglobin molecules, called hemoglobin S, can polymerize upon deoxygenation, causing erythrocytes to adopt a sickled form and to suffer hemolysis and vaso-occlusion. Until recently, only two drug therapies for SCD, which do not even fully address the manifestations of SCD, were approved by the United States (US) Food and Drug Administration. A third treatment was newly approved, while a monoclonal antibody preventing vaso-occlusive crises is also now available. The complex nature of SCD manifestations provides multiple critical points where drug discovery efforts can be and have been directed. These notwithstanding, the need for new therapeutic approaches remains high and one of the recent efforts includes developments aimed at inhibiting the polymerization of hemoglobin S. This review focuses on anti-sickling approaches using peptide-based inhibitors, ranging from individual amino acid dipeptides investigated 30–40 years ago up to more promising 12- and 15-mers under consideration in recent years.
000867774 536__ $$0G:(DE-HGF)POF3-553$$a553 - Physical Basis of Diseases (POF3-553)$$cPOF3-553$$fPOF III$$x0
000867774 588__ $$aDataset connected to CrossRef
000867774 7001_ $$0P:(DE-Juel1)176536$$aOlagunju, Maryam O.$$b1$$ufzj
000867774 7001_ $$0P:(DE-Juel1)132024$$aStrodel, Birgit$$b2
000867774 773__ $$0PERI:(DE-600)2008644-1$$a10.3390/molecules24244551$$gVol. 24, no. 24, p. 4551 -$$n24$$p4551 -$$tMolecules$$v24$$x1420-3049$$y2019
000867774 8564_ $$uhttps://juser.fz-juelich.de/record/867774/files/Invoice_MDPI_molecules-618854.pdf
000867774 8564_ $$uhttps://juser.fz-juelich.de/record/867774/files/Invoice_MDPI_molecules-618854.pdf?subformat=pdfa$$xpdfa
000867774 8564_ $$uhttps://juser.fz-juelich.de/record/867774/files/molecules-24-04551.pdf$$yOpenAccess
000867774 8564_ $$uhttps://juser.fz-juelich.de/record/867774/files/molecules-24-04551.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000867774 8767_ $$8molecules-618854$$92019-12-09$$d2019-12-10$$eAPC$$jZahlung erfolgt
000867774 909CO $$ooai:juser.fz-juelich.de:867774$$popenCost$$pVDB$$pdriver$$pOpenAPC$$popen_access$$popenaire$$pdnbdelivery
000867774 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)180244$$aForschungszentrum Jülich$$b0$$kFZJ
000867774 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)176536$$aForschungszentrum Jülich$$b1$$kFZJ
000867774 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132024$$aForschungszentrum Jülich$$b2$$kFZJ
000867774 9131_ $$0G:(DE-HGF)POF3-553$$1G:(DE-HGF)POF3-550$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lBioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences$$vPhysical Basis of Diseases$$x0
000867774 9141_ $$y2019
000867774 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000867774 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000867774 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000867774 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOLECULES : 2017
000867774 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000867774 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000867774 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000867774 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000867774 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000867774 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000867774 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000867774 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences
000867774 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000867774 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000867774 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000867774 9201_ $$0I:(DE-Juel1)ICS-6-20110106$$kICS-6$$lStrukturbiochemie$$x0
000867774 9801_ $$aAPC
000867774 9801_ $$aFullTexts
000867774 980__ $$ajournal
000867774 980__ $$aVDB
000867774 980__ $$aUNRESTRICTED
000867774 980__ $$aI:(DE-Juel1)ICS-6-20110106
000867774 980__ $$aAPC
000867774 981__ $$aI:(DE-Juel1)IBI-7-20200312